Alterity Therapeutics Limited is developing experimental drugs ATH434 and PBT2 targeting Parkinson's and Alzheimer's diseases. The consensus analyst price target remains steady at $8.67, reflecting consistent market confidence, while some analysts like Adam Vogel project a more optimistic $12 target. Investors should watch clinical trial progress, regulatory approvals, and new partnerships, as these will influence future stock performance and valuations. The company is compared to peers based on profitability, risk, and institutional ownership, important for assessing its financial health.
Ethereum has recently surged past $2,500, approaching a technical pattern called a golden cross, where a short-term moving average crosses above a long-term one, often signaling a bullish trend. However, Ethereum's momentum is currently weak, with re...
Bitwise reported about $100 million in net inflows on August 27 across its U.S. crypto exchange-traded products, with Solana funds leading at roughly $40 million, followed by Bitcoin at $22 million and Hyperliquid at $20 million. The Solana Staking E...
MINISO Group reported a 22.4% year-on-year revenue increase to RMB 11.5 billion in the first half of 2026, led by a 26.2% growth in Chinese mainland sales and a 37.0% rise in North America. The company expanded its store network by 769 stores year-ov...
Precious metals prices rose on Friday, lifting shares of London-listed miners Endeavour Mining and Fresnillo on the FTSE 100. Endeavour Mining's stock increased by 2.26% and Fresnillo's by 1.83%, driven by gains in gold, silver, platinum, and palladi...
Capital B completed a €21 million private placement with institutional investors, including Adam Back and TOBAM, to fund its Bitcoin treasury strategy. The company issued 36.2 million shares with four warrants each, raising net proceeds of about €19....
